StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the medical technology company’s stock.

YAG lasers for cutting soft tissue. But in the late 1990s, companies like Biolase in Irvine, California, gained approval from the US Food and Drug Administration (FDA) for Er,Cr:YSGG lasers for ...

Leading industry players, such as BIOLASE, Inc., are at the forefront of this technological transformation. Renowned globally for their pioneering dental laser products, BIOLASE is spearheading market ...

Short interest in Biolase Inc COM PAR $.001 NEW (OTC:BIOL) decreased during the last reporting period, falling from 21.03K to 9.02K. This put -% of the company's publicly available shares short.